Skip to main content

Lords Science Committee to hear from regulators on the future of regenerative medicine

The House of Lords Science and Technology Committee will next week take evidence from medical regulatory bodies as part of their ongoing inquiry into regenerative medicine.

The Committee will hear from representatives of the Human Tissue Authority, the Human Fertilisation and Embryology Authority, the Health Research Authority and others on Tuesday 8 January. 

The Committee will ask the witnesses for their response to evidence they have received that the regulatory process for regenerative medicine in the UK is too complex, what is being done to harmonise regulation across Europe and internationally, and what efforts they are making to facilitate early dialogue with companies developing regenerative therapies. 

The evidence sessions will start at 3pm on Tuesday 8 January in Committee Room 2A of the House of Lords. The full details are as follows:

From 3pm-4.15pm

  • Professor Sir Kent Woods, Chief Executive, Medicines and Healthcare products Regulatory Agency (MHRA)
  • Hans-Georg Eichler, Senior Medical Officer, European Medicine Agency (EMA)
  • Janet Wisely, Chief Executive, Health Research Agency (HRA).

From 4.15pm-5pm            

  • Peter Thompson, Chief Executive Officer, Human Fertility and Embryology Authority (HFEA)
  • Alan Camp, Chief Executive Officer, Human Tissue Authority (HTA).

The evidence session will be webcast live at and is also open to the public. Journalists wishing to attend should go to Parliament's Cromwell Green Entrance and should allow time for security screening.

Latest tweets


Subscribe to Lords newsletter

Sign up for the House of Lords newsletter for the latest news, debates and business